- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 23
- States / cities
- La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 126
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
- Conditions
- Obesity
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Paul, Minnesota
- Conditions
- Weight Loss, Obesity
- Interventions
- Byetta (exenatide), Weight loss, Metabolic Chamber, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, Exenatide Injection, Ex Inj/ITCA 650
- Other · Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 50
- States / cities
- Chino, California • La Jolla, California • National City, California + 41 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Glipizide
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Renton, Washington
- Conditions
- Gestational Diabetes
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Maisa N. Feghali, MD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Obesity, Impaired Glucose Tolerance
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 25 Years to 60 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Type 2
- Interventions
- Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
- Drug · Device
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Prader-Willi Syndrome
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 13 Years to 20 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 2 Diabetes, Sleep Disordered Breathing
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 100
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide once weekly suspension, Exenatide twice daily
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 58
- States / cities
- Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- AC2993, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 129
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide, Insulin Glargine
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- exenatide, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Concord, California • Fresno, California + 4 more
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650 (exenatide in DUROS)
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Miami Gardens, Florida • Cincinnati, Ohio • San Antonio, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, exenatide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more